Related Experiment Video
Updated: May 6, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
What Does a Positive Alzheimer Disease Blood-Based Biomarker Result Mean in People With Mild Cognitive Impairment?
Jemma Hazan1,2, Kathy Y Liu1,2, Jeremy D Isaacs3,4
1Division of Psychiatry, University College London, London, United Kindgom.
Abstract:
Blood-based biomarkers (BBMs) for Alzheimer disease (AD) offer widely expanded access to biomarker-informed diagnoses in community settings that have previously lacked such resources. However, integrating them into current clinical diagnostic practice presents challenges, particularly in the diagnosis of mild cognitive impairment (MCI). Limited data are available to guide clinicians on when to test, how to counsel patients with MCI and a positive AD BBM result about their risk of dementia progression, or which evidence-based dementia prevention strategies or treatments to recommend. This Perspective article outlines the key challenges faced by clinicians and patients when addressing a diagnosis of "MCI due to AD" and offers suggestions for appropriate pretest counseling and future research directions to address current knowledge gaps.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer Disease l: Introduction
Dementia l: Introduction
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....

